Recombinant CD19 (Inebilizumab Biosimilar) antibody

Catalog No. ABIN7488071

The Mammalian Cells Monoclonal anti-CD19 (Inebilizumab Biosimilar) antibody (ABIN7488071) specifically detects CD19 (Inebilizumab Biosimilar) in ELISA. The antibody is reactive with Human samples.

Quick Overview for Recombinant CD19 (Inebilizumab Biosimilar) antibody (ABIN7488071)

Target: CD19 (Inebilizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This CD19 (Inebilizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-CD19 (Inebilizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Inebilizumab Biosimilar - Anti-CD19 mAb

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for CD19 (Inebilizumab Biosimilar)

Target: CD19 (Inebilizumab Biosimilar)

Target Type: Biosimilar

Background: MEDI-551
Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody that targets the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, which may be usefull to treat neuromyelitis optica spectrum disorder (NMOSD)through B-cell depletion.

CAS-No: 1299440-37-1